New antibody duo tested in quest to control hidden HIV
NCT ID NCT07217379
Summary
This early-stage study is testing the safety of two new antibody drugs, MGD014 and MGD020, in people with HIV who are on stable treatment. Researchers want to see if adding a pill (Vorinostat) that helps expose hidden HIV in the body, or temporarily stopping standard treatment, makes the antibodies more effective. The main goal is to see how safe the combinations are and how the body handles the drugs.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HIV (HUMAN IMMUNODEFICIENCY VIRUS) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kenya Medical Research Institute/Walter Reed Project
NOT_YET_RECRUITINGKericho, Kenya
Contact
-
Moi University Clinical Research Center
NOT_YET_RECRUITINGEldoret, Kenya
Contact
-
University of North Carolina
RECRUITINGChapel Hill, North Carolina, 27514, United States
Contact
Contact Phone: •••-•••-••••
Conditions
Explore the condition pages connected to this study.